Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
20,501
Total Claims
$3.6M
Drug Cost
824
Beneficiaries
$4,332
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-93%
Opioid rate vs peers
0.2% vs 2.6% avg
+306%
Cost per patient vs peers
$4,332 vs $1,068 avg
+100%
Brand preference vs peers
18.0% vs 9.0% avg
Opioid Prescribing
0.2%
Opioid Rate
35
Opioid Claims
$102
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,664 claims · $2.9M
Generic: 16,686 claims · $713K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 272 | $265K |
| Lipase/Protease/Amylase | 189 | $263K |
| Icosapent Ethyl | 363 | $244K |
| Semaglutide | 143 | $221K |
| Sitagliptin Phosphate | 200 | $188K |
| Icosapent Ethyl | 400 | $151K |
| Tenofovir Alafenamide | 83 | $122K |
| Linaclotide | 124 | $115K |
| Linagliptin | 137 | $113K |
| Fluticasone/Umeclidin/Vilanter | 124 | $111K |
| Mirabegron | 98 | $100K |
| Denosumab | 54 | $93K |
| Sitagliptin Phos/Metformin Hcl | 92 | $84K |
| Apixaban | 96 | $73K |
| Dapagliflozin Propanediol | 63 | $68K |
Prescribing Profile
Patient Profile
75
Avg Age
62%
Female
1.36
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data